Evidence map›Paper›PMID 24607955›Full record

ArticleExperimental hematology2014

Phosphorylated c-Mpl tyrosine 591 regulates thrombopoietin-induced signaling.

Veena Sangkhae, Sebastian Jonas Saur, Alexis Kaushansky, Kenneth Kaushansky, Ian Stuart Hitchcock

Open access · greenAbstract read
In one paragraph

Article in Experimental hematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Veena SangkhaeDepartment of Medicine, Stony Brook University, Stony Brook, NY, USA.
Sebastian Jonas SaurDepartment of Hematology/Oncology, Eberhard Karls University Tübingen, Tübingen, Germany.
Alexis KaushanskySeattle Biomedical Research Institute, Seattle, WA, USA.
Kenneth KaushanskyDepartment of Medicine, Stony Brook University, Stony Brook, NY, USA.
Ian Stuart HitchcockDepartment of Hematology/Oncology, Eberhard Karls University Tübingen, Tübingen, Germany. Electronic address: ian.hitchcock@stonybrookmedicine.edu.
Stony Brook University · USUniversity of Tübingen · DECenter for Infectious Disease Research · US

Funding

MOLECULAR AND CELLULAR BIOLOGY OF THROMBOPOIETINR01DK049855 · NIDDK · UNIVERSITY OF WASHINGTON · PI GEDDIS, AMY E, KAUSHANSKY, KENNETH · 1995 to 2013
$5.0M
NIDDK NIH HHS 2R01DK049855-15ANIDDK NIH HHS R01 DK049855
6 · The paper itself

Abstract

Thrombopoietin (TPO) is the primary regulator of platelet production, affecting cell survival, proliferation, and differentiation through binding to and stimulation of the cell surface receptor the cellular myeloproliferative leukemia virus oncogene (c-Mpl). Activating mutations in c-Mpl constitutively stimulate downstream signaling pathways, leading to aberrant hematopoiesis, and contribute to development of myeloproliferative neoplasms. Several studies have mapped the tyrosine residues within the cytoplasmic domain of c-Mpl that mediate these cellular signals; however, secondary signaling pathways are incompletely understood. In this study, we focused on c-Mpl tyrosine 591 (Y591). We found Y591 of wild-type c-Mpl to be phosphorylated in the presence of TPO. Additionally, eliminating Y591 phosphorylation by mutation to Phe resulted in decreased total receptor phosphorylation. Using a Src homology 2/phosphotyrosine-binding (SH2/PTB) domain binding microarray, we identified novel c-Mpl binding partners for phosphorylated Y591, including Src homology region 2 domain-containing phosphatase-1 (SHP-1), spleen tyrosine kinase (SYK) and Bruton's tyrosine kinase (BTK). The functional significance of binding partners was determined through small interfering RNA treatment of Ba/F3-Mpl cells, confirming that the increase in pERK1/2 resulting from removal of Y591 may be mediated by spleen tyrosine kinase. These findings identify a novel negative regulatory pathway that controls TPO-mediated signaling, advancing our understanding of the mechanisms required for successful maintenance of hematopoietic stem cells and megakaryocyte development.

Indexed as

Amino Acid SequenceBlotting, WesternCell LineExtracellular Signal-Regulated MAP KinasesHumansMolecular Sequence DataPhosphorylationReceptors, ThrombopoietinSignal TransductionThrombopoietinTyrosineExtracellular Signal-Regulated MAP KinasesMPL protein, humanReceptors, ThrombopoietinThrombopoietinTyrosine

Identifiers

PMID24607955
PMCPMC5802363
OpenAlexW1984372181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.